Navigation Links
S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies

SINGAPORE, Sept. 18 /PRNewswire/ -- S*BIO Pte Ltd today announced the initiation of multi-center Phase I clinical trials of SB1518, a potent and orally-active JAK2 inhibitor, in patients with leukemia and certain types of lymphoma. These first Phase I trials for SB1518 comprise of ascending dose studies conducted at several leading clinical sites in the United States. The trials are expected to enroll up to 60 patients and are designed to determine the maximum tolerated dose and to assess the pharmacokinetics and overall safety profile of SB1518.

SB1518 is a small molecule JAK2-selective kinase inhibitor which has high potency against both the wild-type JAK2 kinase and the JAK2 kinase with the V617F mutation. The V617F mutation is found in high frequencies in various myeloproliferative disorders such as idiopathic myelofibrosis. SB1518 might also provide an effective treatment for other hematological malignancies with mutations and re-arrangements in the JAK2 gene.

"The entry of SB1518 into the clinical phase marks an important milestone for S*BIO and potentially offers a new targeted therapy for this group of difficult-to-treat patients that represent a significant unmet medical need," said Dr. Jan-Anders Karlsson, CEO of S*BIO. "SB1518 has demonstrated exciting anti-proliferative and anti-tumor activity, combined with excellent tolerability in relevant in vitro and in vivo models. We are pleased to conduct our company's first clinical trials in the United States at well respected centers such as The University of Texas M.D. Anderson Cancer Center, the University of Chicago Medical Center and the Fred Hutchinson Cancer Research Center."

In addition to SB1518, S*BIO has a robust pipeline including SB939, the company's lead histone deacetylase (HDAC) inhibitor, which is currently in Phase I trials in Singapore and Canada. S*BIO's target-driven approach to developing innovative small molecule therapies for cancer is built on a profound understanding of cancer biology, which the company aggressively translates into "best-in-class" and "first-in-class" drugs. The company has a strong team of experienced drug discovery and development scientists, and state-of-the-art infrastructure which includes a comprehensive technology platform covering the drug discovery value chain, from target identification and validation through lead optimisation to pre-clinical and clinical development.

About S*BIO Pte Ltd

S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. Its second compound, SB1518, commenced Phase I clinical trials in 2008 and has received orphan drug designation from the U.S. FDA. A third compound, SB1317, is in pre-clinical development.

In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include Bio*One Capital, Novartis Bioventures and other international funds. More information about S*BIO can be found at

S*BIO Pte Ltd:

Stephen Keith Rhind, Ph.D.

Senior Vice President, Corporate Development

Tel: +65 6827 5000 (Singapore)

Russo Partners:

Tony Russo +1 212-845-4251

Andreas Marathovouniotis +1 212-845-4253

Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies
2. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
3. QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome
4. Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections
5. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
6. Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing
7. Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia
8. Isis Initiates Clinical Trial of CRP Drug
9. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
10. Aegera Initiates a Fifth Phase 1 and 2 Clinical Trial for AEG35156
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
(Date:11/26/2015)... STOCKHOLM , November 26, 2015 ... the potential to use SyMRI to find optimal contrast weighting ... brain tumor metastases, and has signed a research agreement with ... at the hospital. Using SyMRI, it is possible to generate ... parameter settings after the patient has left, thus making it ...
(Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... Global Cell Surface Testing Market: Supplier ... to their offering.  --> ... of the  "2016 Future Horizons and ...
(Date:11/26/2015)... , November 26, 2015 ... --> adds "Global Repaglinide ... "Investigation Report on China Repaglinide Market, ... forecasts data and information to its ... . --> ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Lakeview Health, a Jacksonville-based ... celebrate their sobriety and show through pictures what a positive difference it makes. ... Thanksgiving with the hashtag #FacesOfGratitude on their Facebook, Twitter, and Instagram accounts. ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 25, 2015, officials of ... network, announced the release of a new cutting edge recovery program that has been ... working with drug- and alcohol-addicted individuals with the purpose to free addicts from the ...
(Date:11/25/2015)... Lake, IL (PRWEB) , ... November 25, 2015 , ... ... to announce a recent successful appellate decision obtained by Attorneys Francisco J. Botto and ... case Adcock v. Illinois Workers’ Compensation Comm’n, 2015 IL App (2d) 130884WC. , According ...
(Date:11/25/2015)... ... 25, 2015 , ... Smiles by Stevens is pleased to announce ... wrinkling. While many patients are aware of the benefits of Botox® in the treatment ... those suffering with discomfort, soreness, and pain as a result of Jaw Tension, TMJ ...
(Date:11/25/2015)... ... November 25, 2015 , ... Beddit® has launched a ... tracking systems. The new app features a more intuitive SleepScore™ that rates sleep quality ... you slept. The SleepScore is created by a proprietary algorithm. Beddit analyzes the data ...
Breaking Medicine News(10 mins):